



Oregon Prescription Drug Affordability Board (PDAB) Regular Meeting
Wednesday, November 19, 2025
Minutes approved by the board on Dec. 17, 2025

Web link to the meeting video: https://youtu.be/PB_qhG9rtc0

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20251119-PDAB-document-package.pdf>

Call to order: Chair Shelley Bailey called the meeting to order at 8:00 a.m. and roll was called.

Board members present: Chair Shelley Bailey, Vice Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, John Murray

Absent: Chris Laman

The board provided American Sign Language during the meeting. View at video minute [00:00:38](#).

Election of vice chair: The board elected Dan Hartung as vice chair after the Nov. 16 resignation of Amy Burns from the board. View at video minute [00:01:10](#).

MOTION to nominate Dan Hartung for the position of board vice chair.

Board Vote:

Motion: Dan Hartung

Second: John Murray

Yes: Vice Chair Dan Hartung, Lauri Hoagland, Michele Koder, Dan Kennedy, John Murray, Chair Shelley Bailey

No: None

Absent: Chris Laman

MOTION PASSED 6-0

Declaration of conflict of interest, meetings with entities or individuals related to board activities, or testifying before the Legislature: John Murray provided a statement. View at video minute [00:04:35](#).

Approval of board minutes: Chair Bailey approved by consensus the Oct. 15, 2025 minutes as shown on [Pages 3-4](#) of the agenda materials. View the vote at video minute [00:05:36](#).

PDAB program update: Sarah Young, PDAB executive director, provided a program update. View the video at minute [00:06:26](#).

General public comment: Chair Bailey called on the people who signed up in advance to speak to the board: Lorren Sandt, Caring Ambassadors Program; Dharia McGrew, PhRMA; Jessica McBride, Oregon Coalition for Affordable Prescriptions; Ranier Simons, Community Access



National Network; Primo Castro, Biotechnology Innovation Organization (at the end of the meeting). The board received 12 written comments, which are posted on the [PDAB website](#). View the speakers at video minute [00:09:33](#) and at video minute [03:43:27](#).

Draft annual report: The board discussed the draft annual report. View the report on [Pages 5-42](#). View the discussion at video minute [00:23:17](#).

Vote on policy recommendations for inclusion in the 2025 annual legislative report: The board discussed and voted on 14 policy recommendations for inclusion in the 2025 annual legislative report. Nine motions passed and five motions failed. See below for vote counts for each policy recommendation and see Appendix A for board-approved policy recommendations. View the policies on [Pages 43-51](#). View the discussion at video minute [01:07:08](#).

Policy recommendation 1.a)

PBM reform and pricing transparency: Enact reforms to improve transparency within PBM operations. Specifically, eliminate spread pricing in all state health care market plans and require PBMs to set reimbursement benchmarking based on objective and verifiable cost data, such as the Average Actual Acquisition Cost, National Average Drug Acquisition Cost, or plus cost to dispense; and delink PBM services from drug prices.

MOTION to approve policy recommendation 1.a) as amended by the board today to be included in the annual report.

Board Vote:

Motion: Dan Kennedy

Second: John Murray

Yes: Vice Chair Dan Hartung, Lauri Hoagland, Michele Koder, Dan Kennedy, John Murray, Chair Shelley Bailey

No: None

Absent: Chris Laman

MOTION PASSED 6-0

Policy recommendation 1.c)

Evaluate potential conflicts of interest and rebate-linked incentives among insurance brokers and contracting intermediates, consistent with emerging national models such as Vermont's S.30 (2025).

MOTION to approve policy recommendation 1.c) to be included in the annual report.

Board Vote:

Motion: Dan Kennedy

Second: John Murray

Yes: Dan Kennedy, Chair Shelley Bailey

No: Vice Chair Dan Hartung, Lauri Hoagland, John Murray,

Abstain: Michele Koder

Absent: Chris Laman

MOTION FAILED 2-3



Policy recommendation 2.a)

Pharmacy network access: Adopt an “any-willing-provider” standard, allowing all qualified pharmacies to participate in insurance plan networks.

MOTION to approve policy recommendation 2.a) as amended by the board today to be included in the annual report.

Board Vote:

Motion: Dan Kennedy

Second: John Murray

Yes: Vice Chair Dan Hartung, Lauri Hoagland, Michele Koder, Dan Kennedy, John Murray, Chair Shelley Bailey

No: None

Absent: Chris Laman

MOTION PASSED 6-0

Policy recommendation 2.b)

Pharmacy network access: A permanent corporate activity tax exemption for pharmacies.

MOTION to approve policy recommendation 2.b) as amended by the board today to be included in the annual report.

Board Vote:

Motion: John Murray

Second: Lauri Hoagland

Yes: Vice Chair Dan Hartung, Lauri Hoagland, Michele Koder, Dan Kennedy, John Murray, Chair Shelley Bailey

No: None

Absent: Chris Laman

MOTION PASSED 6-0

Policy recommendation 3.a)

Establish a single statewide PBM for administration of prescription benefits across Medicaid and managed-care programs. The PBM should be selected through a competitive bid process that prioritizes transparency, efficiency, and equitable access.

MOTION to approve policy recommendation 3.a) as amended by the board today to be included in the annual report.

Board Vote:

Motion: John Murray

Second: Dan Kennedy

Yes: Vice Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, John Murray, Chair Shelley Bailey

No: Michele Koder

Absent: Chris Laman

MOTION PASSED 5-1



Policy recommendation 3.b)

Establish a uniform preferred drug list (PDL) applicable to Medicaid and managed care.

MOTION to approve policy recommendation 3.b) as amended by the board today to be included in the annual report.

Board Vote:

Motion: Dan Kennedy

Second: Lauri Hoagland

Yes: Vice Chair Dan Hartung, Lauri Hoagland, Michele Koder, Dan Kennedy, John Murray, Chair Shelley Bailey

No: None

Absent: Chris Laman

MOTION PASSED 6-0

Policy recommendation 3.c)

Evaluate the feasibility and stakeholder impacts of full drug carve-outs or fee-for-services (FFS) reimbursement models for Medicaid pharmacy benefits.

MOTION to approve policy recommendation 3.c) as amended by the board today to be included in the annual report.

Board Vote:

Motion: John Murray

Second: Dan Kennedy

Yes: Vice Chair Dan Hartung, Lauri Hoagland, Michele Koder, Dan Kennedy, John Murray, Chair Shelley Bailey

No: None

Absent: Chris Laman

MOTION PASSED 6-0

Policy recommendation 4.a)

Consider implementing upper payment limit (UPL) authority.

MOTION to approve policy recommendation 4.a) as amended by the board today to be included in the annual report.

Board Vote:

Motion: Dan Kennedy

Second: Lauri Hoagland

Yes: Vice Chair Dan Hartung, Lauri Hoagland, Dan Kennedy

No: Michele Koder, John Murray, Chair Shelley Bailey

Absent: Chris Laman

MOTION FAILED 3-3



Policy recommendation 4.b)

Explore cost-plus pharmacy reimbursement models for public employee programs and implementation of point-of-sale rebate models that directly lower patient out-of-pocket costs.

MOTION to approve policy recommendation 4.b) as amended by the board today to be included in the annual report.

Board Vote:

Motion: John Murray

Second: Dan Kennedy

Yes: Vice Chair Dan Hartung, Michele Koder, Dan Kennedy, John Murray, Chair Shelley Bailey

No: Lauri Hoagland

Absent: Chris Laman

MOTION PASSED 5-1

Policy recommendation 6

Require reporting of data about the 340B program to assess its financial impact, transparency, and equitable distribution of benefits. The report should evaluate which entities receive the largest economic gains, the patient populations served, payer types contributing to revenue, and any potential rebate losses to the state due to 340B provided to Medicaid.

MOTION to approve policy recommendation 6 to be included in the annual report.

Board Vote:

Motion: John Murray

Second: Dan Kennedy

Yes: Vice Chair Dan Hartung, John Murray, Chair Shelley Bailey

No: Lauri Hoagland, Michele Koder, Dan Kennedy

Absent: Chris Laman

MOTION FAILED 3-3

Policy recommendation 7.a)

PDAB scope and governance: Expand PDAB's authority to allow for broader review of Oregon's prescription drug delivery system.

MOTION to approve policy recommendation 7.a) to be included in the annual report.

Board Vote:

Motion: John Murray

Second: Dan Kennedy

Yes: Lauri Hoagland, Michele Koder, Dan Kennedy John Murray, Chair Shelley Bailey

No: Vice Chair Dan Hartung,

Absent: Chris Laman

MOTION PASSED 5-1

Policy recommendation 7.b)

PDAB scope and governance: Amend ORS 192.660 (4) to review trade secret or proprietary information in executive session without media present.



MOTION to approve policy recommendation 7.b) to be included in the annual report.

Board Vote:

Motion: Dan Kennedy

Second: John Murray

Yes: Vice Chair Dan Hartung, Lauri Hoagland, Michele Koder, Dan Kennedy John Murray, Chair Shelley Bailey

No: None

Absent: Chris Laman

MOTION PASSED 6-0

Policy recommendation 8.a)

PDAB scope and governance: Disband the Oregon PDAB.

MOTION to approve policy recommendation 8.a) to be included in the annual report.

Board Vote:

Motion: Dan Kennedy

Second: Shelley Bailey

Yes: None

No: Vice Chair Dan Hartung, Lauri Hoagland, Michele Koder, Dan Kennedy John Murray, Chair Shelley Bailey

Absent: Chris Laman

MOTION FAILED 0-6

Policy recommendation 8.b)

PDAB scope and governance: Consider alternative initiatives to address prescription drug affordability.

MOTION to approve policy recommendation 8. b) to be included in the annual report.

Board Vote:

Motion: Dan Kennedy

Second: Michele Koder

Yes: None

No: Vice Chair Dan Hartung, Lauri Hoagland, Michele Koder, Dan Kennedy John Murray, Chair Shelley Bailey

Absent: Chris Laman

MOTION FAILED 0-6

Board review of methodology for drug reviews and scoring rubric and worksheet: Cortnee Whitlock, senior policy analyst, led the board a discussion about the drug review process. View the documents on [Pages 52-55](#). View at video minute [02:29:03](#).

Continued prescription drug and insulin reviews: Board members discussed the drugs on the list for review. [The updated drug review documents are posted on the on the website](#). View the discussion at video minute [02:54:26](#).



Announcements: Chair Bailey announced the next meeting will be December 17, 2025, at 8 a.m. View at minute [03:45:00](#).

Adjournment: Chair Bailey adjourned the meeting at 11:45 a.m. with all board members in agreement. View at minute [03:45:13](#).

Appendix A: Policy recommendations approved by the board on Nov. 19, 2025

1. PBM reform and pricing transparency:
Enact reforms to improve transparency within PBM operations. Specifically, eliminate spread pricing in all state health care market plans and require PBMs to set reimbursement benchmarking based on objective and verifiable cost data, such as the Average Actual Acquisition Cost, National Average Drug Acquisition Cost, or plus cost to dispense; and delink PBM services from drug prices.
2. Pharmacy network access:
 - a. Adopt an “any-willing-provider” standard, allowing all qualified pharmacies to participate in insurance plan networks.
 - b. A permanent corporate activity tax exemption for pharmacies.
3. Single statewide PBM and uniform preferred drug list:
 - a. Establish a single statewide PBM for administration of prescription benefits across Medicaid and managed-care programs. The PBM should be selected through a competitive bid process that prioritizes transparency, efficiency, and equitable access.
 - b. Establish a uniform preferred drug list (PDL) applicable to Medicaid and managed care.
 - c. Evaluate the feasibility and stakeholder effects of full drug carve-outs or fee-for-services (FFS) reimbursement models for Medicaid pharmacy benefits.
4. Drug pricing oversight and affordability mechanisms:
Explore cost-plus pharmacy reimbursement models for public employee programs and implementation of point-of-sale rebate models that directly lower patient out-of-pocket costs.
5. PDAB scope and governance:
 - a. Expand PDAB’s authority to allow for a broader review of Oregon’s prescription drug delivery system.
 - b. Amend ORS 192.660 (4) to review trade secret or proprietary information in executive session without media present.